BioCentury | Jan 5, 2019
Finance

Ready to launch

...diagnosed, BRCA-mutated advanced ovarian cancer PDUFA date 1Q19 Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) Duobrii (IDP-118...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...failure Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) FDA issues a complete response letter for Duobrii (IDP-118...
BioCentury | Jun 22, 2018
Clinical News

Valeant receives complete response letter for psoriasis candidate

...NYSE:VRX) said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118...
...prodrug. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: Duobrii (IDP-118) Business: Dermatology Sandi Wong Duobrii (IDP-118) Valeant...
BioCentury | Jun 18, 2018
Company News

Valeant slides on psoriasis delay

...Dermatologics said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118...
...is a topical formulation of halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug. Sandi Wong Duobrii (IDP-118) Valeant...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...VII (MPS VII; Sly syndrome) CHMP recommendation 2Q18 Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) Duobrii (IDP-118...
BioCentury | Feb 16, 2018
Clinical News

FDA reviewing Valeant's psoriasis candidate Jemdel

...also reviewing Ortho Dermatologics' IDP-118 to treat plaque psoriasis. Its PDUFA date is June 18. IDP-118...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...AG (Xetra:SAZ) BritLofex lofexidine Opioid withdrawal PDUFA date 2Q18 Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) IDP-118...
BioCentury | Nov 3, 2017
Clinical News

FDA reviewing Valeant psoriasis candidate IDP-118

...an NDA for IDP-118 to treat plaque psoriasis. Its PDUFA date is June 18, 2018. IDP-118...
...a retinoid prodrug. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: IDP-118 Business: Dermatology Allison Johnson IDP-118 tazarotene Valeant...
BioCentury | Nov 2, 2017
Company News

FDA reviewing Valeant's psoriasis candidate

...IDP-118 is a topical formulation of halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug. Allison Johnson IDP-118 tazarotene Valeant...
BioCentury | Jan 20, 2017
Clinical News

IDP-118: Ph III data

...Phase III trial in 215 patients with moderate to severe plaque psoriasis showed that topical IDP-118...
...vehicle-treated controls (45.33% vs. 12.51%, p<0.001). Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: IDP-118...
...clear at weeks 2, 4, 6 and 12 Status: Phase III data Milestone: NA Jaime De Leon IDP-118 Tazarotene Valeant...
Items per page:
1 - 10 of 11